Irrespective of the degree of glycemic control, novel antidiabetic drugs such as SGLT-2 inhibitors—recommended for patients with T2DM and established CV disease, especially HF [44]—can have a potential to improve prognosis also in AS. Here, SLC5A2 is linked to aortic stenosis.